How to image cardiac amyloidosis

Circulation: Cardiovascular Imaging

Volumn 7, Issue 3, 2014, Pages 552-562

  Falk, Rodney H ^c   Quarta, Candida C ^c   Dorbala, Sharmila ^a,b,c  

^a Noninvasive Cardiovascular Imaging Program   (United States)

^b Department of Radiology Division of Nuclear Medicine and Molecular imaging   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Amyloidosis; Cardiac imaging techniques; Echocardiography; Multimodal imaging; Radionuclide imaging

Indexed keywords

AGED; AMYLOIDOSIS; ARTICLE; CARDIAC IMAGING; CARDIOMYOPATHY; CASE REPORT; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; HEART FAILURE; HUMAN; MALE; METHODOLOGY; MULTIMODAL IMAGING; PARAPROTEINEMIA; SCINTISCANNING;

AMYLOIDOSIS; CARDIAC IMAGING TECHNIQUES; ECHOCARDIOGRAPHY; MULTIMODAL IMAGING; RADIONUCLIDE IMAGING;

AGED; AMYLOIDOSIS; CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; ELECTROENCEPHALOGRAPHY; HEART FAILURE; HUMANS; MALE; PARAPROTEINEMIAS;

EID: 84904119887     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.113.001396     Document Type: Article

References (34)

1. Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, Hare JM, Baughman KL, Kasper EK. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004;43:410-415.
2. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic fndings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95:535-537.
3. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S. Systemic cardiac amyloidoses: disease profles and clinical courses of the 3 main types. Circulation. 2009;120:1203-1212.
4. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocar-diography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107:2446-2452.
5. Cappelli F, Porciani MC, Bergesio F, Perlini S, Attanà P, Moggi Pignone A, Salinaro F, Musca F, Padeletti L, Perfetto F. Right ventricular function in AL amyloidosis: characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging. 2012;13:416-422.
6. Bellavia D, Pellikka PA, Dispenzieri A, Scott CG, Al-Zahrani GB, Grogan M, Pitrolo F, Oh JK, Miller FA Jr. Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratifcation in primary systematic (AL) amyloidosis: a 5-year cohort study. Eur Heart J Cardiovasc Imaging. 2012;13:680-689.
7. Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, Marwick TH, Thomas JD. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specifc for the diagnosis of cardiac amyloidosis. Heart. 2012;98:1442-1448.
8. Baccouche H, Maunz M, Beck T, Gaa E, Banzhaf M, Knayer U, Fogarassy P, Beyer M. Differentiating cardiac amyloidosis and hyper-trophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography. 2012;29:668-677.
9. Liu D, Hu K, Niemann M, Herrmann S, Cikes M, Störk S, Gaudron PD, Knop S, Ertl G, Bijnens B, Weidemann F. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6:1066-1072.
10. Buss SJ, Emami M, Mereles D, Korosoglou G, Kristen AV, Voss A, Schellberg D, Zugck C, Galuschky C, Giannitsis E, Hegenbart U, Ho AD, Katus HA, Schonland SO, Hardt SE. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol. 2012;60:1067-1076.
11. Koyama J, Falk RH. Prognostic signifcance of strain Doppler imaging in light-chain amyloidosis. JACC. Cardiovasc Imaging. 2010;3:333-342.
12. Bellavia D, Pellikka PA, Al-Zahrani GB, Abraham TP, Dispenzieri A, Miyazaki C, Lacy M, Scott CG, Oh JK, Miller FA Jr. Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocardiogr. 2010;23:643-652.
13. Modesto KM, Dispenzieri A, Cauduro SA, Lacy M, Khandheria BK, Pellikka PA, Belohlavek M, Seward JB, Kyle R, Tajik AJ, Gertz M, Abraham TP. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J. 2005;26:173-179.
14. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186-193.
15. Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, Finn JP, Judd RM. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215-223.
16. Austin BA, Tang WH, Rodriguez ER, Tan C, Flamm SD, Taylor DO, Starling RC, Desai MY. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC. Cardiovasc Imaging. 2009;2:1369-1377.
17. Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, Cox AT, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Moon JC. Quantifcation of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6:34-39.
18. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloido-sis. J Cardiovasc Magn Reson. 2008;10:54.
19. Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantifcation of extracellular matrix expansion by CMR in infltrative heart disease. JACC. Cardiovasc Imaging. 2012;5:897-907.
20. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M. Role of cardiac magnetic resonance imaging in the detection of cardiac amy-loidosis. JACC. Cardiovasc Imaging. 2010;3:155-164.
21. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51:1022-1030.
22. Wassmuth R, Abdel-Aty H, Bohl S, Schulz-Menger J. Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis. Eur Radiol. 2011;21:1643-1650.
23. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC. Cardiovasc Imaging. 2014;7:133-142.
24. White JA, Kim HW, Shah D, Fine N, Kim KY, Wendell DC, Al-Jaroudi W, Parker M, Patel M, Gwadry-Sridhar F, Judd RM, Kim RJ. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC. Cardiovasc Imaging. 2014;7:143-156.
25. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC. Cardiovasc Imaging. 2013;6:488-497.
26. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC. Native t1 mapping in transthyretin amyloidosis. JACC. Cardiovasc Imaging. 2014; 7: 157-165.
27. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloi-dosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323:508-513.
28. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076-1084.
29. Rapezzi C, Guidalotti P, Salvi F, Riva L, Perugini E. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol. 2008;51:1509-1510; author reply 1510.
30. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195-201.
31. Delahaye N, Dinanian S, Slama MS, Mzabi H, Samuel D, Adams D, Merlet P, Le Guludec D. Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur J Nucl Med. 1999;26:416-424.
32. Tanaka M, Hongo M, Kinoshita O, Takabayashi Y, Fujii T, Yazaki Y, Isobe M, Sekiguchi M. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol. 1997;29:168-174.
33. Coutinho MC, Cortez-Dias N, Cantinho G, Conceição I, Oliveira A, Bordalo e Sá A, Gonçalves S, Almeida AG, de Carvalho M, Diogo AN. Reduced myo-cardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging. 2013;6:627-636.
34. Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, Kero T, Långström B, Granstam SO, Rosengren S, Vedin O, Wassberg C, Wikström G, Westermark P, Sörensen J. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213-220.